BJH - volume 9, issue 3, june 2018
N. De Wilde , F. Offner MD, PhD
Infection prevention is of major importance in patients with haematological malignancies, who are immunocompromised because of disease-related and therapy-related factors. However, in patients receiving anti-B-cell therapies, such as rituximab or ibrutinib (an irreversible BTK inhibitor), measures for infection prevention are hardly studied. In this review we considered vaccine response in patients receiving rituximab treatment and we investigated if an adequate vaccine response can be achieved in patients treated with ibrutinib. For rituximab, no protective titers are obtained in patients with haematological malignancies, but in rheumatoid arthritis 30–50% of patients achieve protective titres. Vaccine response following ibrutinib seems low but it is insufficiently studied to make evidence based recommendations.
(BELG J HEMATOL 2018;9(3):113–7)
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
V. Galle MD, P. Vlummens MD, F. Offner MD, PhD
BJH - 2018, issue Abstract Book BHS, february 2018
dr. A. Delie MD, P. Vlummens MD, N. Van Roy PhD, F. Offner MD, PhD, T. Kerre MD, PhD
BJH - 2018, issue Abstract Book BHS, february 2018
V. Galle MD, P. Vlummens MD, F. Offner MD, PhD
BJH - 2018, issue Abstract Book BHS, february 2018
B. Stamatopoulos , T. Smith , E. Crompot , K. Pieters , R. Clifford , M. Mraz , P. Robbe , A. Burns , A. Timbs , D. Bruce , P. Hillmen , N. Meuleman MD, PhD, P. Mineur MD, R. Firescu , M. Maerevoet MD, V. De Wilde MD, PhD, A. Efira MD, J. Philippé MD, PhD, B. Verhasselt MD, PhD, F. Offner MD, PhD, A. Heger , D. Sims , H. Dreau , A. Schuh
BJH - volume 8, issue Abstract Book BHS, february 2017
P. Vlummens MD, F. Offner MD, PhD
BJH - volume 8, issue Abstract Book BHS, february 2017
P. Vlummens MD, F. Offner MD, PhD
Top
